Table 2.
Adjuvant systemic therapy by time to surgery after diagnosis, The Ruijin cohort.
| Characteristics | Total N = 3144 (%) |
≤ 1week N = 2859 (%) |
1–2 weeks N = 176 (%) |
> 2 weeks N = 109 (%) |
P value |
|---|---|---|---|---|---|
| Chemotherapy | |||||
| No | 834 (26.5) | 740 (25.9) | 52 (29.5) | 42 (38.5) | 0.009 |
| Yes | 2307 (73.4) | 2116 (74.0) | 124 (70.5) | 67 (61.5) | |
| NA | 3 (0.1) | 3 (0.1) | 0 (0) | 0 (0) | |
| Radiation therapy | |||||
| No | 1509 (48.0) | 1359 (47.5) | 91 (51.7) | 59 (54.1) | 0.246 |
| Yes | 1632 (51.9) | 1497 (52.4) | 85 (48.3) | 50 (45.9) | |
| NA | 3 (0.1) | 3 (0.1) | 0 (0) | 0 (0) | |
| Endocrine therapy | |||||
| No | 950 (30.2) | 859 (30.0) | 58 (33.0) | 33 (30.3) | 0.722 |
| Yes | 2191 (69.7) | 1997 (69.9) | 118 (67.0) | 76 (69.7) | |
| NA | 3 (0.1) | 3 (0.1) | 0 (0) | 0 (0) | |
| Targeted therapy | |||||
| No | 2504 (79.6) | 2267 (79.3) | 141 (80.1) | 96 (88.1) | 0.085 |
| Yes | 637 (20.3) | 589 (20.6) | 35 (19.9) | 13 (11.9) | |
| NA | 3 (0.1) | 3 (0.1) | 0 (0) | 0 (0) | |
| Prolonged TTCa | |||||
| No | 1807 (86.5) | 1658 (86.5) | 91 (82.7) | 58 (90.6) | 0.120 |
| Yes | 283 (13.5) | 258 (13.5) | 19 (17.3) | 6 (9.4) | |
| Prolonged TTRb | |||||
| No | 1095 (85.5) | 106 (85.2) | 53 (88.3) | 36 (85.5) | 0.567 |
| Yes | 186 (14.5) | 175 (14.8) | 7 (11.7) | 4 (10.0) | |
aOnly those patients receiving chemotherapy with date information were included into analysis.
bOnly those patients receiving radiotherapy with date information were included into analysis.